Matinas BioPharma Holdings, Inc. (MTNB): Nasdaq/NYSE listing notice — Matinas BioPharma receives NYSE American notice for failure to hold 2024 annual meeting

Matinas BioPharma Holdings, Inc.

On January 6, 2025, Matinas received NYSE American notice for failing to hold 2024 annual meeting, violating Section 704.
Company plans to hold annual meeting no later than December 31, 2025 to cure deficiency.
Common stock continues trading on NYSE American with '.BC' indicator during cure period.
Risks disclosed include sale of MAT 2203 and evaluation of alternatives including winddown or dissolution.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding other.

Exchange: nyse american
Notice: deficiency notice

Exact text from the filing

January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stoc

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-001782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.